Explore a collection of congress presentations and published literature from Arcutis.
Roflumilast foam 0.3% for adolescent and adult patients with seborrheic dermatitis: A randomized, double-blinded, vehicle-controlled, phase 3 trial
Clinical efficacy and patient-reported impacts of roflumilast foam 0.3% in seborrheic dermatitis: An analysis of STRATUM data for patients unresponsive or intolerant to topical corticosteroids
Roflumilast cream 0.3% in patients with chronic plaque psoriasis: individual patient PASI and PASI-HD responses: pooled DERMIS-1 and DERMIS-2 phase 3 trials
Roflumilast cream 0.15% in patients with atopic dermatitis: individual patient EASI responses: pooled INTEGUMENT-1 and INTEGUMENT-2 phase 3 trials
Once-daily roflumilast cream 0.15% for atopic dermatitis: pooled results from INTEGUMENT-1/2 phase 3 trials
Investigator- and patient-rated local tolerability in phase 3 trials of topical roflumilast in patients with psoriasis, seborrheic dermatitis, and atopic dermatitis
Roflumilast cream 0.3% in patients with chronic plaque psoriasis: individual patient response from the pooled DERMIS-1 and DERMIS-2 phase 3 trials